GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cassava Sciences Inc (MEX:SAVA) » Definitions » Institutional Ownership

Cassava Sciences (MEX:SAVA) Institutional Ownership : 17.89% (As of Jun. 25, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Cassava Sciences Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cassava Sciences's institutional ownership is 17.89%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cassava Sciences's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cassava Sciences's Float Percentage Of Total Shares Outstanding is 93.69%.


Cassava Sciences Institutional Ownership Historical Data

The historical data trend for Cassava Sciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cassava Sciences Institutional Ownership Chart

Cassava Sciences Historical Data

The historical data trend for Cassava Sciences can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 22.97 23.08 20.97 20.74 21.16 21.11 20.57 20.97 19.89 17.89

Cassava Sciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Cassava Sciences (MEX:SAVA) Business Description

Traded in Other Exchanges
Address
6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.